# Tempus AI, Inc. Class A Common Stock (TEM) — Stock CV

Tempus AI, Inc. is a $12.9B technology company. Revenue grew 50.4% over the last year, it currently loses money, and it carries $722M of net debt.

> Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful.

## Identity

- **Ticker**: TEM
- **Sector**: Technology
- **Industry**: Services-Computer Programming, Data Processing, Etc.
- **Headquarters**: CHICAGO, IL
- **Employees**: 3 800
- **Website**: https://www.tempus.com
- **Market cap**: $12.9B
- **Last price**: $71.05
- **Financial profile**: Mixed

## Vitals (TTM)

- **Revenue**: $1.43B
- **Net income**: -$254M
- **Free cash flow**: -$263M
- **Net debt**: $722M
- **Revenue growth (YoY)**: 50.4%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 32 |
| Growth | 25 |
| Profitability | 0 |
| Health | 33 |
| Quality | 21 |
| Moat | 20 |

## Qualifications (beginner checklist) — 5 of 9 passed

- [x] Revenue growing — +50.4% YoY
- [ ] Profitable — -$254M TTM
- [x] Profit growing — +65.3% YoY
- [ ] Generates cash — -$263M TTM
- [x] Debt under control — current ratio 3.30
- [x] Established company — $12.9B market cap
- [x] Not printing shares — -99.7% shares over ~5y
- [ ] Proven track record — 0/5 profitable years
- [ ] Financially stable — Altman Z -0.9 — distress

## Experience (career milestones)

- **2026** — Tempus agreed to acquire cancer-testing company Personalis in a deal valued at approximately US$1.5…
- **FY2025** — Revenue crossed $1B: $1.27B for the year
- **Jun 14, 2024** — The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."
- **2015** — Tempus AI, Inc. (formerly Tempus Labs) is an American health technology company founded in 2015 by Eric Lefkofsky in…

## Strengths

- High gross margin (64.0%)
- Revenue growing 50.4% year over year

## Watch-outs

- Not profitable — 17.8% net margin
- Negative free cash flow (-$263.2M)
- Altman Z-Score -0.94 — elevated financial-distress risk
- Thin interest coverage (-3.7×)
- Loss-making in 5 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $258M | -$298M | -$224M |
| FY2022 | $321M | -$334M | -$187M |
| FY2023 | $532M | -$254M | -$249M |
| FY2024 | $693M | -$706M | -$211M |
| FY2025 | $1.27B | -$245M | -$239M |

---

Source: https://stockcv.com/TEM — derived from company filings; may be delayed or incomplete. Information, not investment advice.